LeuproRel™ - For Endometriosis, Uterine Leiomyomata, Central Precocious Puberty Prostatic Cancer | Reliance Life Sciences - LifeSciences
- AzatiRel® (Azacitidine)
- BortiRel® (Bortezomib)
- ErlotiRel® (Erlotinib)
- ImatiRel® (Imatinib)
- Isabis® (Sodium hyaluronate)
- LeuproRel® (Leuprolide)
- ReliCitabine® (Capecitabine)
- ReliDomide® (Lenalidomide)
- ReliTrexed® (Pemetrexed)
- SynoLife™ / SynoLife One™ (Hyaluronate Injection)
- TemoRel® (Temozolomide)
- TerliRel® (Terlipressin)
Business Pharmaceuticals LeuproRel
Leuprolide acetate is a synthetic nonapeptide analogue of naturally occurring gonadotropin-releasing hormone (GnRH or LH-RH). The analogue possesses greater potency than the natural hormone. It is available in a vial which, when mixed with diluents, become a suspension intended as a monthly intramuscular/ subcutaneous injection.
LeuproRel™ DEPOT developed as a depot preparation of Leuprolide acetate using micro-encapsulated formulation demonstrated continuous release of the drug for 4 weeks and the effective suppression of testosterone after a subcutaneous injection monthly.
LeuproRel™ is indicated for endometriosis, uterine leiomyomata (Fibroids), Central Precocious Puberty and Prostatic cancer. LeuproRel™DEPOT is to be administered subcutaneously/ intramuscularly varying the injection site periodically, depending on the indication under the supervision of a physician.
Each composite pack of LeuproRel™DEPOT 3.75 mg contains: One vial of Lyophilized powder of Leuprolide acetate, one ampoule of diluent for reconstitution (2 ml), one sterile syringe, two needles and one alcohol swab. To be reconstituted with diluent.